Nicheloom

Market intelligence for builders — see what's gaining traction before it's crowded.

FinalDose: The first programmable drug to cure all cancers

FinalDose is building the first programmable drug platform - a single smart drug molecule that finds diseased cells by their DNA and destroys them. We’re starting with all cancers.

Details

External ID
101229
Source
YC
Company
FinalDose
Product
FinalDose: The first programmable drug to cure all cancers
Website domain
finaldose.ai
Launched
May 12, 2026
Cohort
Spring 2026
Upvotes
37
Upvotes percentile
0.7761194029850746
Tags
Artificial Intelligence, Gene Therapy, Therapeutics, Genetic Engineering
Fetched at
Sept. 30, 2026, 5 p.m.
Updated at
Sept. 30, 2026, 5 p.m.

Enrichment

Theme
computational biology and personalized therapeutics
Vertical
Healthcare
Function
Hardware & robotics
Audience
B2B
AI stance
Not AI
Project type
Commercial product
Normalized one-liner
programmable drug platform for cancer treatment
Manually corrected
False

Could you build this?

No FinalDose is developing programmable molecular biotechnology and cancer therapeutics, which is fundamentally a wet-lab biology and clinical science challenge.

What it would actually take: Developing this requires molecular biology laboratories, CRISPR/oligonucleotide synthesis, targeted DNA-cleavage biochemistry, and extensive in vitro and in vivo pre-clinical trials. It demands teams of oncology researchers, biochemists, and geneticists, backed by tens of millions of dollars in biotech laboratory infrastructure and regulatory approvals.

Competitors

Other products that read as similar to this one — 14 launches clear the similarity bar, closest 8 shown.

Attention rank: #2 of 15 (itself plus its competitors, highest first — normalized so YC and Product Hunt are compared fairly).

Launched 189 days after the earliest competitor.

Other launches for this product

Same idea, different domain

Nobody's really built a hardware & robotics tool for Horizontal yet.